RE: BNC and this BB Beech;
I would find it incomprehensible to think that Endo, in the midst of a 100 million dollar Urocidin trial, has not floated the human buyout baloon BNC's way.
From the perspective of Endo, the BNC share price is laughably cheap, half that of the trial cost itself. The real buyout offer is coming at some point soon. The question is whether or not we, (we being the shareholders) hear the full scope of the offer...including data from P3B to date.
I doubt many here are going to take the CEO's recommendation to sell or hold at face value, and there will be demands for some form of data disclosure. Too much smelly water has run under this flat-lined 54 cent bridge over the last 6 or 7 years to make a decision sight unseen.